<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35311520</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-6596</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>66</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Antimicrobial agents and chemotherapy</Title>
          <ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.</ArticleTitle>
        <Pagination>
          <StartPage>e0243221</StartPage>
          <MedlinePgn>e0243221</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e02432-21</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/aac.02432-21</ELocationID>
        <Abstract>
          <AbstractText>The epidemiology of macrolide resistance in <i>Mycoplasma</i> (<i>Mycoplasmoides</i>) <i>pneumoniae</i> in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rothstein</LastName>
            <ForeName>Tanner E</ForeName>
            <Initials>TE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cunningham</LastName>
            <ForeName>Scott A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rieke</LastName>
            <ForeName>Rachelle A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mainella</LastName>
            <ForeName>Jill M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mutchler</LastName>
            <ForeName>Melissa M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Robin</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0001-6344-4141</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Infectious Diseases, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
        <NlmUniqueID>0315061</NlmUniqueID>
        <ISSNLinking>0066-4804</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D012338">RNA, Ribosomal, 23S</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015146" MajorTopicYN="N" Type="Geographic">Midwestern United States</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009177" MajorTopicYN="Y">Mycoplasma pneumoniae</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011019" MajorTopicYN="Y">Pneumonia, Mycoplasma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012338" MajorTopicYN="N">RNA, Ribosomal, 23S</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Mycoplasma pneumoniae</Keyword>
        <Keyword MajorTopicYN="Y">antibiotic resistance</Keyword>
        <Keyword MajorTopicYN="Y">macrolides</Keyword>
        <Keyword MajorTopicYN="Y">pneumonia</Keyword>
        <Keyword MajorTopicYN="Y">surveillance studies</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare a conflict of interest. Dr. Patel reports grants from Merck, ContraFect, TenNor Therapeutics Limited and Shionogi. Dr. Patel is a consultant to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, and Qvella; monies are paid to Mayo Clinic. Dr. Patel is also a consultant to Netflix. In addition, Dr. Patel has a patent on <i>Bordetella pertussis</i>/<i>parapertussis</i> PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued. Dr. Patel receives an editor's stipend from IDSA, and honoraria from the NBME, Up-to-Date and the Infectious Diseases Board Review Course. Scott A. Cunningham reports receiving an honorarium from the Antibacterial Resistance Leadership Group.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35311520</ArticleId>
        <ArticleId IdType="pmc">PMC9017374</ArticleId>
        <ArticleId IdType="doi">10.1128/aac.02432-21</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Waites KT-R, et al.. 2011. Mycoplasma and Ureaplasma, p 970–985. In
Versalovic J, Carroll KC, Jorgensen JG, Funke G, Landry ML, Warnock DW (ed), Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.</Citation>
        </Reference>
        <Reference>
          <Citation>Jacobs E, Ehrhardt I, Dumke R. 2015. New insights in the outbreak pattern of Mycoplasma pneumoniae. Int J Med Microbiol
305:705–708. 10.1016/j.ijmm.2015.08.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijmm.2015.08.021</ArticleId>
            <ArticleId IdType="pubmed">26319941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winchell MJ. 2013. Mycoplasma pneumoniae–a national public health perspective. Curr Pediatr Rev
9:324–333. 10.2174/15733963113099990009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/15733963113099990009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waites KB, Ratliff A, Crabb DM, Xiao L, Qin X, Selvarangan R, Tang Y-W, Zheng X, Bard JD, Hong T, Prichard M, Brooks E, Dallas S, Duffy L, Mixon E, Fowler KB, Atkinson TP, Diekema DJ. 2019. Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program. J Clin Microbiol
57:e00968-19. 10.1128/JCM.00968-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.00968-19</ArticleId>
            <ArticleId IdType="pmc">PMC6813023</ArticleId>
            <ArticleId IdType="pubmed">31484701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. 2017. Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev
30:747–809. 10.1128/CMR.00114-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CMR.00114-16</ArticleId>
            <ArticleId IdType="pmc">PMC5475226</ArticleId>
            <ArticleId IdType="pubmed">28539503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loens K, Ieven M. 2016. Mycoplasma pneumoniae: current knowledge on nucleic acid amplification techniques and serological diagnostics. Front Microbiol
7:448. 10.3389/fmicb.2016.00448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2016.00448</ArticleId>
            <ArticleId IdType="pmc">PMC4814781</ArticleId>
            <ArticleId IdType="pubmed">27064893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz MH, Winchell JM. 2016. The evolution of advanced molecular diagnostics for the detection and characterization of Mycoplasma pneumoniae. Front Microbiol
7:232–232. 10.3389/fmicb.2016.00232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmicb.2016.00232</ArticleId>
            <ArticleId IdType="pmc">PMC4781879</ArticleId>
            <ArticleId IdType="pubmed">27014191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lanata MM, Wang H, Everhart K, Moore-Clingenpeel M, Ramilo O, Leber A. 2021. Macrolide-resistant Mycoplasma pneumoniae infections in children, Ohio, USA. Emerg Infect Dis
27:1588–1597. 10.3201/eid2706.203206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid2706.203206</ArticleId>
            <ArticleId IdType="pmc">PMC8153876</ArticleId>
            <ArticleId IdType="pubmed">34013867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitt BH, Sloan LM, Patel R. 2013. Real-time PCR detection of Mycoplasma pneumoniae in respiratory specimens. Diagn Microbiol Infect Dis
77:202–205. 10.1016/j.diagmicrobio.2013.07.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diagmicrobio.2013.07.016</ArticleId>
            <ArticleId IdType="pubmed">24041553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peuchant O, Menard A, Renaudin H, Morozumi M, Ubukata K, Bebear CM, Pereyre S. 2009. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother
64:52–58. 10.1093/jac/dkp160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkp160</ArticleId>
            <ArticleId IdType="pubmed">19429926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onozuka D, Hashizume M, Hagihara A. 2009. Impact of weather factors on Mycoplasma pneumoniae pneumonia. Thorax
64:507–511. 10.1136/thx.2008.111237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/thx.2008.111237</ArticleId>
            <ArticleId IdType="pubmed">19318345</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
